Ukrainian lawmakers back legalization of medical cannabis
Send a link to a friend
[December 22, 2023]
(Reuters) - Ukrainian lawmakers voted to legalize the medical use
of cannabis on Thursday after activists and supporters called for the
step in order to treat millions of people including soldiers wounded in
the war with Russia.
The bill was backed by 248 lawmakers, senior lawmaker Yaroslav
Zhelezniak wrote on Telegram messenger. Selling or supplying cannabis
for recreational use would remain a criminal offence.
Mariia Mezentseva, a lawmaker who had pushed for the bill in parliament,
said medical cannabis was needed by 6 million Ukrainians, including
cancer patients, civilians with post-traumatic stress disorder (PTSD)
and wounded soldiers.
The war launched by Russia in February 2022 has killed tens of thousands
of people, destroyed settlements and driven millions of people from
their homes. The fighting rages on with no sign it is about to end.
The bill must be signed by President Volodymyr Zelenskiy before it
becomes law. It would only come into force six months after it is
officially published.
Opposition lawmaker Yuliia Tymoshenko, prime minister from 2007 to 2010,
had staunchly opposed the legislation, arguing that recreational drug
use would proliferate in Ukraine.
[to top of second column]
|
Danish Prime Minister Mette Frederiksen addresses Ukrainian
lawmakers during a parliament session, amid Russia's attack on
Ukraine, in Kyiv, Ukraine September 6, 2023. REUTERS/Andrii
Nesterenko/File Photo
The legislation would impose strict
controls on the production of medical cannabis, including 24-hour
video surveillance accessible by the police of producers who would
have to be licensed, Zhelezniak said.
Medicine containing medical cannabis would only be available by
electronic prescription under the bill, he said.
(Reporting by Yuliia Dysa; writing by Tom Balmforth; editing by
Jonathan Oatis)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |